GlassScriptPhysician profile
Eddie G Benge
NPI 1609982453
$839.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270.72 | 2019 | |
| Amgen INC. | $178.08 | 2019 | |
| Janssen Biotech, INC. | $70.96 | 2019 | |
| Ucb, INC. | $65.64 | 2019 | |
| Celgene Corporation | $45.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.96 | 2019 | |
| Lilly USA, LLC | $35.08 | 2019 | |
| Pfizer INC. | $29.87 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $27.30 | 2019 | |
| Genentech USA, INC. | $17.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.83 | 2019 | |
| Sobi, INC | $15.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2019 | |
| Gilead Sciences, INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Benge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.